Britain's medical regulator will examine all the data from trials of the COVID-19 vaccine developed by Oxford and AstraZeneca, including which dosing regimen is best to use, the regulator's chief executive said on Wednesday.
"Our regulatory review is all encompassing We will look at all available data," June Raine, chief executive of the Medicines and Healthcare products Regulatory Agency (MHRA), told lawmakers after a study showed the vaccine had efficacy of 62% for trial participants given two full doses, but 90% for a smaller sub-group given a half, then a full dose.
"Clearly, we have great interest into the possible reasons for the different doses having a different efficacy," she said.
"The position is we will look at every piece of evidence part of that will be to examine with great rigour, the basis for the appropriate dosage regimen," she added.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Next Virus Could Be More Lethal, Warns Oxford University Covid Vaccine Creator Even Single Vaccine Dose Cuts COVID-19 Infection Rate, New UK Study Finds Covishield Comprises Over 90% Of 12.76 Crore Covid Vaccines Given So Far: Government Data Mamata Banerjee's Sunday Ultimatum To CBI For Death Penalty In Rape-Murder How Extreme Weather Is Leading To Rise In Child Marriages In Pakistan Who Is Jasveen Sangha, "Ketamine Queen" Charged With Matthew Perry's Death Explained: Occupational English Test For Healthcare Professionals "I Am Sorry": KTR Apologises For Remarks After Woman's Panel Begins Probe Hyderabad Restaurant Raids: Food Safety Violations Found In And Around DLF Cyber City, Gachibowli Track Latest News Live on NDTV.com and get news updates from India and around the world.